No drug was administered until completion of the first trimester. As the patient could not afford interferon, hydroxyurea was administered to control the blood counts and symptoms. At 30 weeks, ultrasound abdomen revealed the presence of a meningocele. She delivered a dead fetus with the meningocele at the 34th week of pregnancy. She was restarted on imatinib with further advice for strict contraception and to stop the drug before any planned pregnancy.
The limited published literature suggests that imatinib is safe in pregnancy [1] [2] [3] [4] . However, animal experiments suggest it is unsafe. Imatinib, an inhibitor of abl-tyrosine kinase, is teratogenic in mouse and rats when administered during organogenesis at doses of >100 mg/kg, causing exencephaly or encephalocele, and absent or reduced frontal and absent parietal bones [5] . The most critical period for teratogenicity is the first trimester as this period correlates with active organogenesis. Our patient had been exposed to imatinib during conception and for 6 weeks thereafter with development of a meningocele and a fatal outcome. The few reports of delivery of a normal fetus, even with intake of imitanib during pregnancy, should not suggest that the drug is safe. Our case clearly highlights that the drug is potentially teratogenic. To the best of our knowledge this is the first such complication reported in humans. We strongly recommend effective contraception for all patients who are on imatinib. 
